Please login to the form below

Not currently logged in

PMEA Company of the Year (<£150m)

Highly Commended


Summary of work

Celgene is a multinational biopharmaceutical company committed to improving the lives of patients worldwide through by delivering innovative and life-changing drugs.

The company’s mission is to build a major global biopharmaceutical corporation while focusing on the discovery and the development of products for the treatment of cancer and other severe immune, inflammatory conditions.

There are more than 200 clinical trials at major medical centres using compounds from Celgene. These investigational compounds are being actively studied in clinical trials for patients with incurable haematological and solid tumour cancers, including:

  • Multiple myeloma
  • Myelodysplastic syndromes
  • Chronic lymphocytic leukaemia
  • Non-Hodgkin's lymphoma
  • Glioblastoma
  • Ovarian cancer
  • Pancreatic cancer
  • Prostate cancer
By utilising the latest advances in molecular and cellular research to develop novel therapies that target the mechanisms of disease at their source, Celgene is making potentially life-saving treatments a reality for the millions of patients around the world fighting cancer and other debilitating diseases.

Celgene supports patient organisations, according to the following principles:
  • Independence of patient organisations in terms of their political judgement, policies and activities
  • Respect with the views and decisions of each partner having equal weight
  • Celgene will not request, nor shall patient organisations undertake, the promotion of a particular prescription only medicine
  • Transparency; financial and non-financial support provided by Celgene will always be clearly acknowledged
  • Celgene welcomes broad funding of patient organisations from multiple sources.
Celgene UK & Ireland supports Leukaemia CARE, Myeloma UK, Rarer Cancers Forum and MDS UK Patient Support Group

Judges comments

“Celgene has clearly made real progress in the last 12 month. Its passion and growth in confidence is demonstrated even though the business is more complex now. Brilliantly managed, it is very focused on marketing excellence and the importance of it throughout the organisation.”

Key dates

Entry deadline 25 August 2023
Extended entry deadline 1 September 2023*
*additional fee applies
Judging Day 10 October 2023
Company/Team of the Year Interviews 3 November 2023
PMEA Event 22 November 2023